Novavax, Inc Equity-NMS: NVAX

Healthcare

Biotechnology

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :	$8.08
Open :	$8.15
Today's high :	$8.67
Today's low :	$8.07
52W low :	$5.01
52W high :	$15.22
1Y :	-41.33%
5Y :	-93.53%
EPS(TTM): :	2.25
Shares O/S :	162.42 M
Market cap :	1.39 B

What is the share price of Novavax, Inc today?

Novavax, Inc (NVAX) share price as of September 17, 2025, is $8.54. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of Novavax, Inc?

Yes, Indian Investors can invest in the Novavax, Inc (NVAX) Share by opening an international trading account with Angel One.

How can I purchase Novavax, Inc shares in India?

Purchasing Novavax, Inc (NVAX) share from India can be done by:

Directly: By opening an international trading account with Angel One. The process would include KYC verification.
The account activation takes a few minutes to a few hours, after which you can start buying Novavax, Inc (NVAX) by making deposits in US dollars.
Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of Novavax, Inc?

Yes, you can purchase fractional shares of Novavax, Inc (NVAX) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of Novavax, Inc?

The market capitalization of Novavax, Inc on September 17, 2025, is $1.39 B.

In which sector Novavax, Inc belongs?

Novavax, Inc operates in the Healthcare sector, specifically in the Biotechnology industry.

What documents are required to invest in Novavax, Inc stocks?

In order to invest in Novavax, Inc (NVAX) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.